EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models

Jiaojiao Luo, Wanyi Ng, Yangli Liu, Lixin Wang, Chenyuan Gong, Yufu Zhou, Cheng Fang, Shiguo Zhu, Chao Yao

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03706-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Jiaojiao Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 20120…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Lymphocytes, Tumor-Infiltrating, Benzofurans, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-infiltrating lymphocyte (TIL) deficiency is the most conspicuous obstacle to limit the cancer immunotherapy. Immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibody, have achieved great success in clinical practice. However, due to the limitation of response rates of ICIs, some patients fail to benefit from monotherapy. Thus, novel combination therapy that could improve the response rates emerges as new strategies for cancer treatment. Here, we reported that the natural product rocaglamide (RocA) increased tumor-infiltrating T cells and promoted Th17 differentiation of CD4 + TILs. Despite RocA monotherapy upregulated PD-1 expression of TILs, which was considered as the consequence of T cell activation, combining RocA with anti-PD-1 antibody significantly downregulated the expression of PD-1 and promoted proliferation of TILs. Taken together, these findings demonstrated that RocA could fuel the T cell anti-tumor immunity and revealed the remarkable potential of RocA as a therapeutic candidate when combining with the ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingBenzofuransProgrammed Cell Death 1 ReceptorCell DifferentiationMiceAnimalsHumansNeoplasmsDrug Resistance, NeoplasmMice, Inbred C57BLFemaleT-LymphocytesCell Line, Tumor

Stichwörter der Autor:innen

Anti-PD-1 antibodyImmune checkpoint blockadeRocaglamideTh17 cells

Substanzen

rocaglamideImmune Checkpoint InhibitorsBenzofuransProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. zhushiguo@shutcm.edu.cn.
  • Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. yaochao@shutcm.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai

Zitieren

APA

Luo, J., Ng, W., Liu, Y., Wang, L., Gong, C., Zhou, Y., Fang, C., Zhu, S., & Yao, C. (2024). Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03706-5

Vancouver

Luo J, Ng W, Liu Y, Wang L, Gong C, Zhou Y, et al. Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03706-5

BibTeX
@article{Luo2024,
  author = {Luo, Jiaojiao and Ng, Wanyi and Liu, Yangli and Wang, Lixin and Gong, Chenyuan and Zhou, Yufu and Fang, Cheng and Zhu, Shiguo and Yao, Chao},
  title = {Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03706-5}
}
Kostenlos starten →